Your browser doesn't support javascript.
loading
Assessing early changes in plasma HER2 levels is useful for predicting therapeutic response in advanced breast cancer: A multicenter, prospective, noninterventional clinical study.
Kang, Yi-Kun; Si, Yi-Ran; Ju, Jie; Jia, Zhu-Qing; Hu, Nan-Lin; Dong, Hao; Wang, Xue; Yue, Jian; Jiang, Pei-Di; Li, Zhao-Liang; Zhang, Yun-Yun; Wang, Yan; Xu, Bing-He; Yuan, Peng.
Afiliación
  • Kang YK; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Si YR; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Ju J; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Jia ZQ; Beijing Unicare Hospital, Beijing, China.
  • Hu NL; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Dong H; Questgenomics, Nanjing, China.
  • Wang X; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Yue J; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Jiang PD; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Li ZL; Questgenomics, Nanjing, China.
  • Zhang YY; Questgenomics, Nanjing, China.
  • Wang Y; Gnomegen, San Diego, California, USA.
  • Xu BH; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Yuan P; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Cancer Med ; 12(5): 5323-5333, 2023 03.
Article en En | MEDLINE | ID: mdl-36281495
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos